Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Advanced or Recurrent Solid Tumors
Breast Neoplasms
Ovarian Cancer, Epithelial
Ewing Sarcoma
Small Cell Lung Carcinoma
Prostate Cancer
Pancreas Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2011-02-01

Last Posted Date: 2019-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 113

Registration Number: NCT01286987

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States

and more 12 locations

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tigecycline
Drug: placebo
Drug: moxifloxacin
Drug: 100 mL 0.9% Sodium Chloride intravenous

First Posted Date: 2011-02-01

Last Posted Date: 2011-05-24

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01287793

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: PF-04449913

First Posted Date: 2011-01-31

Last Posted Date: 2024-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT01286467

Locations: 🇺🇸
Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
Keck Hospital of University of Southern California, Los Angeles, California, United States
🇺🇸
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 6 locations

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Phase 1

Completed

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

Interventions: Drug: fesoterodine

First Posted Date: 2011-01-31

Last Posted Date: 2012-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT01286454

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05231023
Other: Placebo

First Posted Date: 2011-01-28

Last Posted Date: 2016-11-18

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT01285518

Locations: 🇺🇸
Cetero Research, San Antonio, Texas, United States
🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Miramar, Florida, United States

and more 1 locations

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Biological: Anrukinzumab
Other: placebo

First Posted Date: 2011-01-26

Last Posted Date: 2014-11-18

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT01284062

Locations: 🇫🇷
CHU Hotel-Dieu, Nantes CEDEX 1, France
🇺🇸
Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States
🇺🇸
Endoscopy Center of Connecticut, LLC, Hamden, Connecticut, United States

and more 72 locations

Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

Phase 2

Completed

Conditions: Onychomycosis

Interventions: Drug: AN2690 Solution, 5.0%

First Posted Date: 2011-01-17

Last Posted Date: 2018-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT01278394

Locations: 🇲🇽
Instituto Dermatologico Jalisciense, Guadalajara, Mexico
🇲🇽
IMIC, Mexico City, Mexico

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Treatment B
Drug: Treatment A

First Posted Date: 2011-01-17

Last Posted Date: 2011-04-07

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT01277991

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: CP-690,550
Drug: Placebo/CP-690,550

First Posted Date: 2011-01-13

Last Posted Date: 2014-09-19

Lead Sponsor: Pfizer

Target Recruit Count: 901

Registration Number: NCT01276639

Locations: 🇺🇸
Menter Dermatology Research Institute, Dallas, Texas, United States
🇲🇽
Centro de Dermatologia de Monterrey, Monterrey, Nuevo Leon, Mexico
🇵🇱
Katedra i Klinika Dermatologii, Wenerologii i Alergologii Akademii Medycznej we Wroclawiu, Wroclaw, Poland

and more 71 locations

A Study Of PF-05175157 In Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05175157 or Placebo

First Posted Date: 2011-01-11

Last Posted Date: 2011-10-12

Lead Sponsor: Pfizer

Target Recruit Count: 63

Registration Number: NCT01274663

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy